arrow
M

Muharrem Müftüoğlu

university of texas system
H指数:23
被引数:2,783

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
2023-12-013
OAAI
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

在新诊断的继发性AML以及低甲基化药物失败后的MDS或CMML中,阿扎胞苷,维尼托克和培沃尼地他的1/2期研究

2023-07-0817
OAAI
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
2023-06-2910
OAAI
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (vol 28, pg 557, 2022)
2022-04-282
OAAI
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

干细胞结构推动骨髓增生异常综合征的进展并预测对基于维尼托克的治疗的反应

2022-03-0334
OAAI
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA &ITCCAT2&IT induce myeloid malignancies via unique SNP-specific RNA mutations

癌症相关的rs6983267 SNP及其伴随的长链非编码RNA和ITCCAT2及其通过独特的SNP特异性RNA突变诱导髓系恶性肿瘤

2018-03-2253
OAAI
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide
2018-01-1527
OAAI